0001209191-19-043922.txt : 20190731 0001209191-19-043922.hdr.sgml : 20190731 20190731200406 ACCESSION NUMBER: 0001209191-19-043922 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190729 FILED AS OF DATE: 20190731 DATE AS OF CHANGE: 20190731 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BRYANT DOUGLAS C CENTRAL INDEX KEY: 0001406652 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-10961 FILM NUMBER: 19990506 MAIL ADDRESS: STREET 1: C/O QUIDEL CORPORATION STREET 2: 12544 HIGH BLUFF DRIVE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: QUIDEL CORP /DE/ CENTRAL INDEX KEY: 0000353569 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 942573850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12544 HIGH BLUFF DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 8585521100 MAIL ADDRESS: STREET 1: 12544 HIGH BLUFF DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: MONOCLONAL ANTIBODIES INC /DE/ DATE OF NAME CHANGE: 19910210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-07-29 0 0000353569 QUIDEL CORP /DE/ QDEL 0001406652 BRYANT DOUGLAS C 12544 HIGH BLUFF DRIVE, SUITE 200 SAN DIEGO CA 92130 1 1 0 0 President & CEO Common Stock 2019-07-29 4 M 0 21789 15.19 A 323231 D Common Stock 2019-07-29 4 S 0 21789 57.78 D 301442 D Non-Qualified Stock Options 15.19 2019-07-29 4 M 0 21789 0.00 D 2022-03-02 Common Stock 21789 75731 D The weighted average sale price for these transactions was $57.78 per share, with a range of $57.125 to $58.98. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares sold at each separate price. 60,196 shares vested on 03/02/2014; 30,098 shares vested on 03/02/2015; and 30,099 shares vested on 03/02/2016. All transactions reported herein were effected pursuant to a pre-established 10b5-1 trading plan. Robert J. Bujarski, attorney-in-fact for Douglas C. Bryant 2019-07-31